Radioimmunodetection and radioimmunotherapy of breast cancer

Tumori

Volumn 83, Issue 2, 1997, Pages 552-557

  Riva, Pietro ^a   Franceschi, Giancarlo ^a   Gentile, Rossella ^a   Riva, Nada ^a   Casi, Michela ^a  

^a BUFALINI HOSPITAL   (Italy)

Author keywords

Breast cancer; Monoclonal antibody; Radioimmunodetection; Radioimmunotherapy

Indexed keywords

ANTIBODY CONJUGATE; INDIUM 111; IODINE 131; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M;

BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONFERENCE PAPER; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; PATIENT SELECTION; PLEURA EFFUSION; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 0030825520     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169708300215     Document Type: Conference Paper

References (29)

1. Bischof Delaloye A., Delaloye B.: Tumor imaging with monoclonal antibodies. Sem. Nucl. Med., 25, 144-164, 1995.
2. Buckman R., De Angelis C., Shaw P., Covens A., Osbome R., Kerr I.: Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol. Oncol., 47: 102-109, 1992.
3. Chung J.K., Jang J.J., Lee D.S., Lee M.C., Koh C.S.: Tumor concentration and distribution of carcinoembryonic antigen measured by in vitro quantitative autoradiography. J. Nucl. Med., 35: 1499-1505, 1994.
4. Colcher M., Roselli M., Carrasquillo J.A., Reynolds J.C., Larson S.M., Sugarbaker P., Tuttle S.E., Martin E.W.: Tumor targeting with monoclonal antibody B72.3. Nucl. Med. Biol., 16: 137-142, 1989.
5. Contegiacomo A., Alimandi M., Muraro R., Pizzi C., Calderopoli R., De Marchis L., Sgambato A., Pettinato G., Petrella G., De Filippo M.R.: Expression of epitopes of the tumour-associated glycoprotein 72 and clinical-pathological correlations in mammary carcinomas. Eur. J. Cancer, 30A: 813-820, 1994.
6. De Nardo G., De Nardo S., Kukis D., Diril H., Suey C., Meares C.: Strategies for enhancement of radioimmunotherapy. Nucl. Med. Biol., 18: 633-639, 1991.
7. De Nardo S., Krainer E.L., Richam C.M., Salako Q.A., Perez E.A., O'Grady L.F., et al.: Radioimmunotherapy of breast cancer with Y-90/In-111 BrE-3: current clinical results and therapeutic potential. J. Nucl. Med, 34: 53P, 1993.
8. De Nardo S., O'Grady L.F., Richman C.M., De Nardo G.: Overview of radioimmunotherapy in advanced breast cancer using 1-131 chimeric L6. Adv. Exp. Med. Biol., 353: 203-211, 1994.
9. Goodman G.E., Hellstrom I., Yelton D.E., Murray J.L., O'Hara S., Meaker E., Zeigler L., Palazollo P., Nicaise C., Usakewicz J.: Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol. Immunother., 36: 267-273, 1993.
10. Guadagni F, Roselli M., Nieroda C., Dansky-Ullmann G., Schlom J., Greiner J.W.: Biological response modifiers as adjuvants in monoclonal antibody based treatment in vivo, 7: 591-599, 1993.
11. Guadagni F., Roselli M., Schlom J., Greiner J.W.: In vitro and in vivo regulation of human tumor antigen expression by human recombinant interferons: a review. Int. J. Biol. Markers, 9: 53-60, 1994.
12. Hird V., Snook C., Kosmas B., Dhokia S., Stewart P., Mason J., Lambert C., Meares C., Epenetos A.: Intraperitoneal radioimmunotherapy with yttrium-90 labeled immunoconjugates in monoclonal antibodies application in oncology (ed. A. Epenetos). Chapman and Hall, London, pp. 267-271, 1991.
13. Kelsey J. (Ed.) Breast cancer, Epidemiology Reviews. Vol. 15, n. 1, 1993.
14. Kalofonos H.P., Kosmas C., Hird V., Snook D.E., Epenetos A.A.: Targeting of tumours with murine and reshaped human monoclonal antibodies against placental alkaline phosphatase: immunolocalisation, pharmacokinetics and immune response. Eur. J. Cancer, 30A: 1842-1850, 1994.
15. Lind P., Lechner P., Ratschek M., Klima G., Koltringer P., Steindorfer P., Eber O.: The immunoscintigraphic use of Tc-99m-labeled monoclonal anti-CEA antibodies (BW 431/26) in patients with suspected primary, recurrent and metastatic breast cancer. Int. J. Cancer, 46: 865-869, 1991.
16. Loevinger R., Berman M.: A schema for absorbed dose calculation for biologically distributed radionuclides. Pamphlet n. 1, J. Nucl. Med., 9 (suppl. 1): 7-14, 1968.
17. Leung S.O., Karacay H., Losman M.J., Griffiths G.L., Goldenberg D.M., Hansen H.J.: Bacterial expression of a kemptide fusion protein facilitates 32P labeling of a humanized anti-carcinoembryonic antigen (hMN-14) antibody fragment. Cancer Res., 55: 5968s-5972s, 1995.
18. MIRD Pamphlet, n. 11. The Society of Nuclear Medicine, N.Y., 1985.
19. Paganelli G., Pervez S., Siccardi A.G., Rowlinson G., Deleide G., Chiolerio F., Malcavati M., Scassellati G.A., Epenetos A.A.: Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies. Int. J. Cancer, 45: 1184-1189, 1990.
20. Riva P., Moscatelli G., Paganelli G., Benini S., Siccardi A.: Antibody guided tumor diagnosis: an Italian experience on CEA-expressing tumors. Int. J. Cancer, Supplement 2: 114-120, 1988.
21. Schier D.M., Stemmer S.M., Johnson T., Kasliwal R., Lear J.S.: High-dose 90Y Mx-diethylelenetriaminepentaacetic acid (DTPA-BrE-3) and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial: Cancer Res., 55: 5921s-5924s, 1995.
22. Schlom J., Molinolo A., Simpson J.F., Siler K., Roselli M., Hiffide G., et al.: Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J. Natl. Cancer Inst., 82: 763-771, 1990.
23. Schlom J., Siler K., Milenic D.E., Eggensperger D., Colcher D., Miller L.S., Houchens D., Cheng R., Kaplan D., Goeckeler W.: Monoclonal antibody-based therapy of a human tumor xenograft with a 177-lutetium-labeled immunoconjugate. Cancer Res., 51: 2889-2896, 1991.
24. Seccamani E., Tattanelli M., Mariani M., Spranzi E., Scassellati G.A., Siccardi A.G.: A simple qualitative determination of human antibodies to murine immunoglobulins (HAMA) in serum samples. Nucl. Med. Biol., 16: 167-170, 1989.
25. Sharkey R.M., Juweid M., Shevitz J., Behr T., Dunn R., Swayne L.C., Wong G.Y., Blumenthal R.D., Griffiths G.I., Siegel J.A., Leung S., Hansen H.J., Goldenberg D.M.: Evaluation of a complementarity-determining region-grafted (humanized) anticarcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res., 55: 5935s-5945s, 1995.
26. Siccardi A.G., Buraggi G.L., Callegaro L., Centi Colella A., De Filippi P.G., Galli G., Mariani G., Masi R., Palumbo R., Riva P.: Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab')2 fragments of an anti-carcinoembryonic antigen monoclonal antibody: a multicentre study. Cancer Res., 49: 3095-3103, 1989.
27. Stickney D.R., Gridley D.S., Kirk G.A., Slater J.M.: Enhancement of monoclonal antibody binding to melanoma with single dose radiation or hyperthermia. Natl. Cancer Inst. Monogr., 3: 47-52, 1985.
28. Tjandra J.J., Sacks N.P., Thompson C.H., Leyden M.J., Andrews M.J., Pietersz G.A.: The detection of axillary lymph node metastases from breast cancer by radiolabeled monoclonal antibodies: a prospective study. Br. J. Cancer, 59: 296-302, 1989.
29. Thor A.D., Edgerton S.M. Monoclonal antibodies reactive with human breast or ovarian carcinoma: in vivo applications. Semin. Nucl. Med., 19: 295-308, 1989.